Trial Sites

Edelife is now enrolling pregnant women who may be expecting an XLHED-affected boy. However, pregnant woman with confirmed or suspected hereditary ectodermal dysplasia (HED) unsure of their XLHED status may be eligible for screening. Early referral is essential as screening visit must occur between weeks 19-24 of pregnancy.

Clinical site investigators are international experts in ectodermal dysplasia diagnosis and care. To refer a patient or for more information, please contact a study investigator.